Immunology drugs
40 drugs with cited findings from FDA review packages and EMA assessment reports. Every figure on every page cites its source document and page.
By condition
By drug class
Endpoints & rating scales explained
Tremfya
Johnson & Johnson · 4746 cited findings
Kevzara
Sanofi · 4572 cited findings
Rinvoq
AbbVie Inc. · 4308 cited findings
Bimzelx
UCB SA · 4209 cited findings
Cosentyx
Novartis AG · 3943 cited findings
Skyrizi
AbbVie Inc. · 3590 cited findings
Humira
AbbVie Inc. · 3502 cited findings
Olumiant
Eli Lilly and Company · 3295 cited findings
Sotyktu
Bristol-Myers Squibb Company · 3196 cited findings
Omvoh
Eli Lilly and Company · 2738 cited findings
Velsipity
Pfizer Inc. · 2642 cited findings
Cibinqo
Pfizer Inc. · 2559 cited findings
Dupixent
Regeneron Pharmaceuticals, Inc. · 2469 cited findings
Stelara
Johnson & Johnson · 2434 cited findings
Zeposia
Bristol-Myers Squibb Company · 2426 cited findings
Xeljanz
Pfizer Inc. · 2401 cited findings
Otezla
Amgen Inc. · 2270 cited findings
Vyvgart
argenx SE · 2138 cited findings
Jyseleca
Alfasigma S p A · 2003 cited findings
Nemluvio
Galderma · 1978 cited findings
Ocrevus
Roche Holding AG · 1614 cited findings
Taltz
Eli Lilly and Company · 1594 cited findings
Ebglyss
Almirall S A · 1434 cited findings
Saphnelo
AstraZeneca PLC · 1135 cited findings
Rystiggo
UCB SA · 1035 cited findings
Simponi
CENTOCOR ORTHO BIOTECH INC · 950 cited findings
Cimzia
UCB SA · 917 cited findings
Imaavy
Johnson & Johnson · 820 cited findings
Kyntheum
LEO A S · 737 cited findings
Entyvio
Takeda Pharmaceutical Company Limited · 696 cited findings
tildrakizumab
Almirall S A · 634 cited findings
Benlysta
GSK plc · 620 cited findings
Spevigo
LEO A S · 565 cited findings
Sylvant
Recordati B V · 482 cited findings
Skilarence
Almirall S A · 333 cited findings
Erelzi
Novartis AG · 245 cited findings
Simponi Aria
Johnson & Johnson · 224 cited findings
Nordimet
Nordic B V · 123 cited findings
Zinbryta
BIOGEN · 61 cited findings
Jylamvo
Oresund · 38 cited findings
Educational reference only — not medical or investment advice.